Company Filing History:
Years Active: 2021
Title: Ho Woong Kang: Innovator in Therapeutic Proteins
Introduction
Ho Woong Kang is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. His innovative work focuses on enhancing the pharmacological properties of fusion proteins.
Latest Patents
Ho Woong Kang holds a patent for a fusion protein comprising a CCL3 variant. This invention is designed to improve in vivo persistency, protein stability, and pharmacological activity. The patent specifically details a fusion protein that includes a CCL3 variant and an immunoglobulin Fc region, which can be utilized as a therapeutic agent for conditions such as lymphopenia, cancer, or infection. The CCL3 variant is characterized by the deletion of an N-terminal amino acid from the wild-type CCL3α or CCL3β, along with a specific amino acid substitution.
Career Highlights
Kang is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on the development of innovative therapeutic solutions that address critical health challenges.
Collaborations
Throughout his career, Ho Woong Kang has collaborated with notable colleagues, including Su Youn Nam and Jong Gyun Kim. These collaborations have fostered a productive environment for research and development in the field of therapeutic proteins.
Conclusion
Ho Woong Kang's contributions to the field of biotechnology, particularly through his patent on fusion proteins, highlight his role as an innovator in therapeutic solutions. His work continues to impact the development of treatments for various medical conditions.